SCHEMBL802823

SCHEMBL802823

C=C(C)C(=O)Oc1ccc2c(ccc3cc(OC(=O)C(=C)C)ccc32)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 1/20 0.50
KMT2A Q03164 4/20 0.46
ATM Q13315 1/20 0.46
CA12 O43570 2/20 0.41
CA9 Q16790 2/20 0.41
NCEH1 Q6PIU2 1/20 0.39
MAPT P10636 4/20 0.39
TDP1 Q9NUW8 2/20 0.39
MEN1 O00255 2/20 0.39
ALDH1A1 P00352 2/20 0.39
HPGD P15428 1/20 0.39
KDM4E B2RXH2 4/20 0.38
GLA P06280 3/20 0.38
GAA P10253 3/20 0.38
POLB P06746 1/20 0.38
FLT3 P36888 1/20 0.37
CA2 P00918 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.36
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20998247 0.95 ELANE (0.50) ELANEKMT2AATMCA12CA9
SCHEMBL18522453 0.94 KDM4E (0.46) ELANEKMT2AATMMAPTMEN1
SCHEMBL12321312 0.94 ELANE (0.45) ELANEKMT2AATMCA12CA9
SCHEMBL803231 0.93 ELANE (0.56) ELANEKMT2AATMCA12CA9
SCHEMBL10048329 0.92 ELANE (0.44) ELANEKMT2AATMCA12CA9
SCHEMBL14907505 0.92 ALDH1A1 (0.51) ELANEKMT2AATMNCEH1MAPT
SCHEMBL18194809 0.92 ELANE (0.44) ELANEKMT2AATMCA12CA9
SCHEMBL18087356 0.91 ELANE (0.43) ELANEKMT2AATMCA12CA9
SCHEMBL19156409 0.91 ELANE (0.50) ELANEKMT2AATMCA12CA9
SCHEMBL23507793 0.89 ELANE (0.42) ELANEKMT2AATMCA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 864 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12043781-B2 Liquid-crystalline medium MERCK PATENT GMBH (DE) 2024-07-23 US disclosed
US-12043781-B2 Liquid-crystalline medium MERCK PATENT GMBH (DE) 2024-07-23 US disclosed
EP-4400561-A1 LIQUID-CRYSTAL MEDIUM Merck Patent GmbH (DE) 2024-07-17 EP disclosed
WO-2024133363-A1 LIQUID-CRYSTAL MEDIUM MERCK PATENT GMBH (DE) 2024-06-27 WO disclosed
WO-2024132893-A1 LIQUID-CRYSTALLINE MEDIUM MERCK PATENT GMBH (DE) 2024-06-27 WO disclosed
WO-2024126567-A1 LIQUID-CRYSTALLINE MEDIUM MERCK PATENT GMBH (DE) 2024-06-20 WO disclosed
US-20240067879-A1 Liquid-crystal medium MERCK PATENT GMBH (DE) 2024-02-29 US disclosed
US-20240067879-A1 Liquid-crystal medium MERCK PATENT GMBH (DE) 2024-02-29 US disclosed
EP-3924447-B1 POLYMERISABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS MERCK PATENT GMBH (DE) 2024-01-24 EP disclosed
EP-4306614-A1 LIQUID-CRYSTALLINE MEDIUM Merck Patent GmbH (DE) 2024-01-17 EP disclosed
WO-2011029510-A1 LIQUID-CRYSTAL DISPLAY MERCK PATENT GMBH (DE) 2011-03-17 WO disclosed
US-20110051049-A1 LIQUID-CRYSTAL DISPLAY MERCK PATENT GESELLSCHAFT (DE) 2011-03-03 US disclosed
US-20110051049-A1 LIQUID-CRYSTAL DISPLAY MERCK PATENT GESELLSCHAFT (DE) 2011-03-03 US disclosed
US-20100272925-A1 LIQUID-CRYSTAL DISPLAY MERCK PATENT GESELLSCHAFT (DE) 2010-10-28 US disclosed
US-20100272925-A1 LIQUID-CRYSTAL DISPLAY MERCK PATENT GESELLSCHAFT (DE) 2010-10-28 US disclosed
EP-2243812-A2 Liquid crystal display Merck Patent GmbH (DE) 2010-10-27 EP disclosed
US-20100252777-A1 LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-10-07 US disclosed
US-20100252777-A1 LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-10-07 US disclosed
WO-2010089092-A1 LIQUID CRYSTALLINE MEDIUM AND LIQUID CRYSTAL DISPLAY MERCK PATENT GMBH (DE) 2010-08-12 WO disclosed
WO-2009118086-A1 LIQUID CRYSTAL DISPLAY MERCK PATENT GMBH (DE) 2009-10-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100272925-A1 LIQUID-CRYSTAL DISPLAY KLK3, BPHL, LPXN ELANE 402/4885KMT2A 4232/4885ATM 2608/4885
US-20110051049-A1 LIQUID-CRYSTAL DISPLAY VCL, LPXN, ACP3 ELANE 884/4885KMT2A 3389/4885ATM 2221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.